Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 20:22 ET | Source: InnoCare Pharma

Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.
December 08, 2025 21:04 ET | Source: InnoCare Pharma

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster.
November 27, 2025 20:55 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
October 30, 2025 20:30 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China

ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors.
October 29, 2025 23:51 ET | Source: InnoCare Pharma

Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025

Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors.
September 07, 2025 20:30 ET | Source: InnoCare Pharma

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore

InnoCare's HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with R/R MZL.
August 21, 2025 09:24 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China

The first patient has been dosed in the registrational trial of InnoCare's BCL2 inhibitor mesutoclax for patients with BTK inhibitor treated MCL in China.